Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL NEUROMYELITIS OPTICA TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL NEUROMYELITIS OPTICA TREATMENT MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY BASED MODEL
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL NEUROMYELITIS OPTICA TREATMENT MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES MODEL
5 INDUSTRY INSIGHTS
5.1 PATENT ANALYSIS
5.1.1 PATENT LANDSCAPE
5.1.2 USPTO NUMBER
5.1.3 PATENT EXPIRY
5.1.4 EPIO NUMBER
5.1.5 PATENT STRENGTH AND QUALITY
5.1.6 PATENT CLAIMS
5.1.7 PATENT CITATIONS
5.1.8 PATENT LITIGATION AND LICENSING
5.1.9 FILE OF PATENT
5.1.10 PATENT RECEIVED CONTRIES
5.1.11 TECHNOLOGY BACKGROUND
5.2 DRUG TREATMENT RATE BY MATURED MARKETS
5.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
5.4 PATIENT FLOW DIAGRAM
5.5 KEY PRICING STRATEGIES
5.6 KEY PATIENT ENROLLMENT STRATEGIES
5.7 INTERVIEWS WITH SPECIALIST
5.8 OTHER KOL SNAPSHOTS
6 EPIDEMIOLOGY
6.1 INCIDENCE OF ALL BY GENDER
6.2 TREATMENT RATE
6.3 MORTALITY RATE
6.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
6.5 PATIENT TREATMENT SUCCESS RATES
7 MERGERS AND ACQUISITION
7.1 LICENSING
7.2 COMMERCIALIZATION AGREEMENTS
8 REGULATORY FRAMEWORK
8.1 REGULATORY APPROVAL PROCESS
8.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
8.3 REGULATORY APPROVAL PATHWAYS
8.4 LICENSING AND REGISTRATION
8.5 POST-MARKETING SURVEILLANCE
8.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
9 PIPELINE ANALYSIS
9.1 CLINICAL TRIALS AND PHASE ANALYSIS
9.2 DRUG THERAPY PIPELINE
9.3 PHASE III CANDIDATES
9.4 PHASE II CANDIDATES
9.5 PHASE I CANDIDATES
9.6 OTHERS (PRE-CLINICAL AND RESEARCH)
TABLE 1 GLOBAL CLINICAL TRIAL MARKET FOR NEUROMYELITIS OPTICA TREATMENT MARKET
Company Name Therapeutic Area
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE NEUROMYELITIS OPTICA TREATMENT MARKET
Phase Number of Projects
Preclinical/Research Projects XX
Clinical Development XX
Phase I XX
Phase II XX
Phase III XX
U.S. Filed/Approved But Not Yest Marketed XX
Total XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE NEUROMYELITIS OPTICA TREATMENT MARKET
Therapeutic Area Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE NEUROMYELITIS OPTICA TREATMENT MARKET
Technology Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR NEUROMYELITIS OPTICA TREATMENT MARKET
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
10 MARKETED DRUG ANALYSIS
10.1 DRUG
10.1.1 BRAND NAME
10.1.2 GENERICS NAME
10.2 THERAPEUTIC INDIACTION
10.3 PHARACOLOGICAL CLASS OD THE DRUG
10.4 DRUG PRIMARY INDICATION
10.5 MARKET STATUS
10.6 MEDICATION TYPE
10.7 DRUG DOSAGES FORM
10.8 DOSAGES AVAILABILITY
10.9 PACKAGING TYPE
10.1 DRUG ROUTE OF ADMINISTRATION
10.11 DOSING FREQUENCY
10.12 DRUG INSIGHT
10.13 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.
10.13.1 FORECAST MARKET OUTLOOK
10.13.2 CROSS COMPETITION
10.13.3 THERAPEUTIC PORTFOLIO
10.13.4 CURRENT DEVELOPMENT SCENARIO
11 MARKET ACCESS
11.1 10-YEAR MARKET FORECAST
11.2 CLINICAL TRIAL RECENT UPDATES
11.3 ANNUAL NEW FDA APPROVED DRUGS
11.4 DRUGS MANUFACTURER AND DEALS
11.5 MAJOR DRUG UPTAKE
11.6 CURRENT TREATMENT PRACTICES
11.7 IMPACT OF UPCOMING THERAPY
12 R & D ANALYSIS
12.1 COMPARATIVE ANALYSIS
12.2 DRUG DEVELOPMENTAL LANDSCAPE
12.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES
12.4 THERAPEUTIC ASSESSMENT
12.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS
13 MARKET OVERVIEW
13.1 DRIVERS
13.2 RESTRAINTS
13.3 OPPORTUNITIES
13.4 CHALLENGES
14 GLOBAL NEUROMYELITIS OPTICA TREATMENT MARKET, BY TYPE
14.1 OVERVIEW
14.2 WITH AQUAPORIN-4 ANTIBODIES
14.3 WITHOUT AQUAPORIN-4 ANTIBODIES
15 GLOBAL NEUROMYELITIS OPTICA TREATMENT MARKET, BY DISEASE TYPE
15.1 OVERVIEW
15.2 RELAPSING FORM
15.3 MONOPHASIC FORM
16 GLOBAL NEUROMYELITIS OPTICA TREATMENT MARKET, BY TREATMENT TYPE
16.1 OVERVIEW
16.2 MEDICATION
16.2.1 APPROVED/MARKETED TREATMENT
16.2.1.1. IMMUNOSUPPRESSANT
16.2.1.1.1. AZATHIOPRINE
16.2.1.1.2. MYCOPHENOLATE
16.2.1.1.3. RITUXIMAB
16.2.1.1.4. CORTICOSTEROID
16.2.1.1.4.1 METHYLPREDNISOLONE
16.2.1.1.4.2 PREDNISONE
16.2.1.1.4.3 OTHERS
16.2.1.1.5. OTHERS
16.2.1.2. MONOCLONAL ANTIBODY
16.2.1.2.1. ECULIZUMAB
16.2.1.2.2. INEBILIZUMAB
16.2.1.2.3. SATRALIZUMAB-MWGE
16.2.1.2.4. OTHERS
16.2.1.3. ANTI-EPILEPTIC MEDICATIONS
16.2.1.3.1. GABAPENTIN
16.2.1.3.2. CARBAMAZEPINE
16.2.1.3.3. OTHERS
16.2.1.4. ANTI-SPASMODICS
16.2.1.4.1. BACLOFEN
16.2.1.4.2. TIZANIDINE
16.2.1.4.3. OTHERS
16.2.1.5. ANTI-DEPRESSANTS
16.2.1.5.1. AMITRIPTYLINE
16.2.1.5.2. DULOXETINE
16.2.1.5.3. OTHERS
16.2.1.6. ANALGESICS
16.2.1.6.1. TRAMADOL
16.2.1.6.2. OPIATES
16.2.1.6.3. OTHERS
16.2.1.7. OTHERS
16.2.2 PIPELINE MEDICATION
16.2.2.1. ANTI-FCRN BATOCLIMAB
16.2.2.2. ABX-1431
16.2.2.3. TG-1101
16.2.2.4. NDC-1308
16.2.2.5. OTHERS
16.3 PLASMAPHERESIS
16.3.1 FILTERS
16.3.1.1. PLASMA EXCHANGE
16.3.1.2. DOUBLE FILTRATION PLASMAPHERESIS
16.3.1.3. IMMUNOADSORPTION
16.3.1.4. OTHERS
16.3.2 MACHINES
16.3.2.1. BY TYPE
16.3.2.1.1. THERAPEUTIC APHAERESISI MACHINE
16.3.2.1.2. PLASMAPHERESIS MACHINE
16.3.2.1.3. CENTRIFUGES
16.3.2.1.4. OTHERS
16.3.2.2. BY MODALITY
16.3.2.2.1. TROLLEY MOUNTED
16.3.2.2.2. BENCH TOP
16.3.2.2.3. OTHERS
16.3.3 REPLACEMENT FLUIDS
16.3.3.1. ALBUMIN
16.3.3.2. ELECTROLYTE
16.3.3.3. HYDROXYETHYL STARCH
16.3.3.4. FFP
16.3.3.5. PURIFIED PROTEIN PRODUCTS
16.3.3.6. OTHERS
16.3.4 DISPOSABLES
16.3.4.1. SINGLE USE TUBING SETS
16.3.4.2. INJECTION NEEDLE
16.3.4.3. SPARE FILTERS
16.3.4.4. SOLUTIONS
16.3.4.5. OTHERS
16.3.5 OTHERS
16.4 STEM CELL THERAPY
16.4.1 HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
16.4.1.1. AUTOLOGOUS
16.4.1.2. ALLOGENEIC
16.4.2 MESENCHYMAL STEM CELLS
16.5 OTHERS
17 GLOBAL NEUROMYELITIS OPTICA TREATMENT MARKET, BY DRUG TYPE
17.1 OVERVIEW
17.2 BRANDED
17.2.1 SOLIRIS
17.2.2 UPLIZNA
17.2.3 ENSPRYNG
17.2.4 OTHERS
17.3 GENERICS
18 GLOBAL NEUROMYELITIS OPTICA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
18.1 OVERVIEW
18.2 ORAL
18.2.1 TABLETS
18.2.2 SUSPENSION
18.2.3 OTHERS
18.3 PARENTERAL
18.3.1 INTRAVENOUS
18.3.2 SUBCUTANEOUS
18.3.3 OTHERS
18.4 OTHERS
19 GLOBAL NEUROMYELITIS OPTICA TREATMENT MARKET, BY POPULATION TYPE
19.1 OVERVIEW
19.2 MALE
19.2.1 PEDIATRIC
19.2.2 ADULTS
19.2.3 GERIATRIC
19.3 FEMALE
19.3.1 PEDIATRIC
19.3.2 ADULTS
19.3.3 GERIATRIC
20 GLOBAL NEUROMYELITIS OPTICA TREATMENT MARKET, BY AGE GROUP
20.1 OVERVIEW
20.2 PEDIATRIC
20.3 ADULTS
20.4 GERIATRIC
21 GLOBAL NEUROMYELITIS OPTICA TREATMENT MARKET, BY END USER
21.1 OVERVIEW
21.2 HOSPITALS
21.2.1 BY TYPE
21.2.1.1. PUBLIC
21.2.1.2. PRIVATE
21.2.2 BY LEVEL
21.2.2.1. TIER 1
21.2.2.2. TIER 2
21.2.2.3. TIER 3
21.3 SPECIALTY CLINICS
21.4 HOME HEALTHCARE
21.5 ACADEMIC AND RESEARCH INSTITUTES
21.6 OTHERS
22 GLOBAL NEUROMYELITIS OPTICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL
22.1 OVERVIEW
22.2 DIRECT TENDER
22.3 RETAIL SALES
22.3.1 OFFLINE SALES
22.3.1.1. HOSPITAL PHARMACIES
22.3.1.2. RETAIL PHARMACIES
22.3.1.3. OTHERS
22.3.2 ONLINE SALES
22.3.2.1. E-STORES
22.3.2.2. COMPANY WEBSITE
22.3.2.3. OTHERS
22.4 OTHERS
23 GLOBAL NEUROMYELITIS OPTICA TREATMENT MARKET, BY GEOGRAPHY
23.1 GLOBAL NEUROMYELITIS OPTICA TREATMENT MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
23.1.1 NORTH AMERICA
23.1.1.1. U.S.
23.1.1.2. CANADA
23.1.1.3. MEXICO
23.1.2 EUROPE
23.1.2.1. GERMANY
23.1.2.2. FRANCE
23.1.2.3. U.K.
23.1.2.4. HUNGARY
23.1.2.5. LITHUANIA
23.1.2.6. AUSTRIA
23.1.2.7. IRELAND
23.1.2.8. NORWAY
23.1.2.9. POLAND
23.1.2.10. ITALY
23.1.2.11. SPAIN
23.1.2.12. RUSSIA
23.1.2.13. TURKEY
23.1.2.14. BELGIUM
23.1.2.15. NETHERLANDS
23.1.2.16. SWITZERLAND
23.1.2.17. REST OF EUROPE
23.1.3 ASIA-PACIFIC
23.1.3.1. JAPAN
23.1.3.2. CHINA
23.1.3.3. SOUTH KOREA
23.1.3.4. INDIA
23.1.3.5. AUSTRALIA
23.1.3.6. SINGAPORE
23.1.3.7. THAILAND
23.1.3.8. MALAYSIA
23.1.3.9. INDONESIA
23.1.3.10. PHILIPPINES
23.1.3.11. VIETNAM
23.1.3.12. REST OF ASIA-PACIFIC
23.1.4 SOUTH AMERICA
23.1.4.1. BRAZIL
23.1.4.2. ARGENTINA
23.1.4.3. PERU
23.1.4.4. REST OF SOUTH AMERICA
23.1.5 MIDDLE EAST AND AFRICA
23.1.5.1. SOUTH AFRICA
23.1.5.2. SAUDI ARABIA
23.1.5.3. UAE
23.1.5.4. EGYPT
23.1.5.5. KUWAIT
23.1.5.6. ISRAEL
23.1.5.7. REST OF MIDDLE EAST AND AFRICA
23.1.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
24 GLOBAL NEUROMYELITIS OPTICA TREATMENT MARKET, COMPANY LANDSCAPE
24.1 COMPANY SHARE ANALYSIS: GLOBAL
24.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
24.3 COMPANY SHARE ANALYSIS: EUROPE
24.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
24.5 MERGERS & ACQUISITIONS
24.6 NEW PRODUCT DEVELOPMENT & APPROVALS
24.7 EXPANSIONS
24.8 REGULATORY CHANGES
24.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
25 GLOBAL NEUROMYELITIS OPTICA TREATMENT MARKET, SWOT AND DBMR ANALYSIS
26 GLOBAL NEUROMYELITIS OPTICA TREATMENT MARKET, COMPANY PROFILE
26.1 PHARMA MANUFACTURES
26.1.1 CORESTEMCHEMON INC.
26.1.1.1. COMPANY OVERVIEW
26.1.1.2. REVENUE ANALYSIS
26.1.1.3. GEOGRAPHIC PRESENCE
26.1.1.4. PRODUCT PORTFOLIO
26.1.1.5. RECENT DEVELOPMENTS
26.1.2 ASTRAZENECA
26.1.2.1. COMPANY OVERVIEW
26.1.2.2. REVENUE ANALYSIS
26.1.2.3. GEOGRAPHIC PRESENCE
26.1.2.4. PRODUCT PORTFOLIO
26.1.2.5. RECENT DEVELOPMENTS
26.1.3 HARBOUR BIOMED
26.1.3.1. COMPANY OVERVIEW
26.1.3.2. REVENUE ANALYSIS
26.1.3.3. GEOGRAPHIC PRESENCE
26.1.3.4. PRODUCT PORTFOLIO
26.1.3.5. RECENT DEVELOPMENTS
26.1.4 TG THERAPEUTICS
26.1.4.1. COMPANY OVERVIEW
26.1.4.2. REVENUE ANALYSIS
26.1.4.3. GEOGRAPHIC PRESENCE
26.1.4.4. PRODUCT PORTFOLIO
26.1.4.5. RECENT DEVELOPMENTS
26.1.5 ENDECE
26.1.5.1. COMPANY OVERVIEW
26.1.5.2. REVENUE ANALYSIS
26.1.5.3. GEOGRAPHIC PRESENCE
26.1.5.4. PRODUCT PORTFOLIO
26.1.5.5. RECENT DEVELOPMENTS
26.1.6 ALEXION PHARMACEUTICALS
26.1.6.1. COMPANY OVERVIEW
26.1.6.2. REVENUE ANALYSIS
26.1.6.3. GEOGRAPHIC PRESENCE
26.1.6.4. PRODUCT PORTFOLIO
26.1.6.5. RECENT DEVELOPMENTS
26.1.7 HORIZON THERAPEUTICS PLC
26.1.7.1. COMPANY OVERVIEW
26.1.7.2. REVENUE ANALYSIS
26.1.7.3. GEOGRAPHIC PRESENCE
26.1.7.4. PRODUCT PORTFOLIO
26.1.7.5. RECENT DEVELOPMENTS
26.1.8 F. HOFFMANN-LA ROCHE LTD
26.1.8.1. COMPANY OVERVIEW
26.1.8.2. REVENUE ANALYSIS
26.1.8.3. GEOGRAPHIC PRESENCE
26.1.8.4. PRODUCT PORTFOLIO
26.1.8.5. RECENT DEVELOPMENTS
26.1.9 PFIZER INC.
26.1.9.1. COMPANY OVERVIEW
26.1.9.2. REVENUE ANALYSIS
26.1.9.3. GEOGRAPHIC PRESENCE
26.1.9.4. PRODUCT PORTFOLIO
26.1.9.5. RECENT DEVELOPMENTS
26.1.10 AMNEAL PHARMACEUTICALS LLC.
26.1.10.1. COMPANY OVERVIEW
26.1.10.2. REVENUE ANALYSIS
26.1.10.3. GEOGRAPHIC PRESENCE
26.1.10.4. PRODUCT PORTFOLIO
26.1.10.5. RECENT DEVELOPMENTS
26.1.11 ZYDUS GROUP
26.1.11.1. COMPANY OVERVIEW
26.1.11.2. REVENUE ANALYSIS
26.1.11.3. GEOGRAPHIC PRESENCE
26.1.11.4. PRODUCT PORTFOLIO
26.1.11.5. RECENT DEVELOPMENTS
26.1.12 JUBILANT CADISTA PHARMACEUTICALS INC.
26.1.12.1. COMPANY OVERVIEW
26.1.12.2. REVENUE ANALYSIS
26.1.12.3. GEOGRAPHIC PRESENCE
26.1.12.4. PRODUCT PORTFOLIO
26.1.12.5. RECENT DEVELOPMENTS
26.1.13 HIKMA PHARMACEUTICALS PLC
26.1.13.1. COMPANY OVERVIEW
26.1.13.2. REVENUE ANALYSIS
26.1.13.3. GEOGRAPHIC PRESENCE
26.1.13.4. PRODUCT PORTFOLIO
26.1.13.5. RECENT DEVELOPMENTS
26.1.14 VIATRIS INC.
26.1.14.1. COMPANY OVERVIEW
26.1.14.2. REVENUE ANALYSIS
26.1.14.3. GEOGRAPHIC PRESENCE
26.1.14.4. PRODUCT PORTFOLIO
26.1.14.5. RECENT DEVELOPMENTS
26.1.15 SEBELA PHARMACEUTICALS
26.1.15.1. COMPANY OVERVIEW
26.1.15.2. REVENUE ANALYSIS
26.1.15.3. GEOGRAPHIC PRESENCE
26.1.15.4. PRODUCT PORTFOLIO
26.1.15.5. RECENT DEVELOPMENTS
26.1.16 NOVARTIS AG
26.1.16.1. COMPANY OVERVIEW
26.1.16.2. REVENUE ANALYSIS
26.1.16.3. GEOGRAPHIC PRESENCE
26.1.16.4. PRODUCT PORTFOLIO
26.1.16.5. RECENT DEVELOPMENTS
26.1.17 ACCORD-UK LTD
26.1.17.1. COMPANY OVERVIEW
26.1.17.2. REVENUE ANALYSIS
26.1.17.3. GEOGRAPHIC PRESENCE
26.1.17.4. PRODUCT PORTFOLIO
26.1.17.5. RECENT DEVELOPMENTS
26.1.18 TEVA PHARMACEUTICALS USA, INC.
26.1.18.1. COMPANY OVERVIEW
26.1.18.2. REVENUE ANALYSIS
26.1.18.3. GEOGRAPHIC PRESENCE
26.1.18.4. PRODUCT PORTFOLIO
26.1.18.5. RECENT DEVELOPMENTS
26.1.19 ALKEM LABS
26.1.19.1. COMPANY OVERVIEW
26.1.19.2. REVENUE ANALYSIS
26.1.19.3. GEOGRAPHIC PRESENCE
26.1.19.4. PRODUCT PORTFOLIO
26.1.19.5. RECENT DEVELOPMENTS
26.1.20 STRIDES PHARMA INC.
26.1.20.1. COMPANY OVERVIEW
26.1.20.2. REVENUE ANALYSIS
26.1.20.3. GEOGRAPHIC PRESENCE
26.1.20.4. PRODUCT PORTFOLIO
26.1.20.5. RECENT DEVELOPMENTS
26.1.21 CONCORD BIOTECH
26.1.21.1. COMPANY OVERVIEW
26.1.21.2. REVENUE ANALYSIS
26.1.21.3. GEOGRAPHIC PRESENCE
26.1.21.4. PRODUCT PORTFOLIO
26.1.21.5. RECENT DEVELOPMENTS
26.2 MEDICAL DEVICE MANUFACTURE
26.2.1 ASAHI KESEI CORPORATION
26.2.1.1. COMPANY OVERVIEW
26.2.1.2. REVENUE ANALYSIS
26.2.1.3. GEOGRAPHIC PRESENCE
26.2.1.4. PRODUCT PORTFOLIO
26.2.1.5. RECENT DEVELOPMENTS
26.2.2 HAEMONETICS CORPORATION
26.2.2.1. COMPANY OVERVIEW
26.2.2.2. REVENUE ANALYSIS
26.2.2.3. GEOGRAPHIC PRESENCE
26.2.2.4. PRODUCT PORTFOLIO
26.2.2.5. RECENT DEVELOPMENTS
26.2.3 MILTENYI BIOTEC AND/OR ITS AFFILIATES
26.2.3.1. COMPANY OVERVIEW
26.2.3.2. REVENUE ANALYSIS
26.2.3.3. GEOGRAPHIC PRESENCE
26.2.3.4. PRODUCT PORTFOLIO
26.2.3.5. RECENT DEVELOPMENTS
26.2.4 GRIFOLS, S.A.
26.2.4.1. COMPANY OVERVIEW
26.2.4.2. REVENUE ANALYSIS
26.2.4.3. GEOGRAPHIC PRESENCE
26.2.4.4. PRODUCT PORTFOLIO
26.2.4.5. RECENT DEVELOPMENTS
26.2.5 OCTAPHARMA AG
26.2.5.1. COMPANY OVERVIEW
26.2.5.2. REVENUE ANALYSIS
26.2.5.3. GEOGRAPHIC PRESENCE
26.2.5.4. PRODUCT PORTFOLIO
26.2.5.5. RECENT DEVELOPMENTS
26.2.6 3M (SOLVENTUM)
26.2.6.1. COMPANY OVERVIEW
26.2.6.2. REVENUE ANALYSIS
26.2.6.3. GEOGRAPHIC PRESENCE
26.2.6.4. PRODUCT PORTFOLIO
26.2.6.5. RECENT DEVELOPMENTS
26.2.7 B. BRAUN SE
26.2.7.1. COMPANY OVERVIEW
26.2.7.2. REVENUE ANALYSIS
26.2.7.3. GEOGRAPHIC PRESENCE
26.2.7.4. PRODUCT PORTFOLIO
26.2.7.5. RECENT DEVELOPMENTS
26.2.8 FRESENIUS SE & CO. KGAA
26.2.8.1. COMPANY OVERVIEW
26.2.8.2. REVENUE ANALYSIS
26.2.8.3. GEOGRAPHIC PRESENCE
26.2.8.4. PRODUCT PORTFOLIO
26.2.8.5. RECENT DEVELOPMENTS
26.2.9 INFOMED SA
26.2.9.1. COMPANY OVERVIEW
26.2.9.2. REVENUE ANALYSIS
26.2.9.3. GEOGRAPHIC PRESENCE
26.2.9.4. PRODUCT PORTFOLIO
26.2.9.5. RECENT DEVELOPMENTS
26.2.10 SB-KAWASUMI LABORATORIES, INC.
26.2.10.1. COMPANY OVERVIEW
26.2.10.2. REVENUE ANALYSIS
26.2.10.3. GEOGRAPHIC PRESENCE
26.2.10.4. PRODUCT PORTFOLIO
26.2.10.5. RECENT DEVELOPMENTS
26.2.11 TERUMO BCT, INC.
26.2.11.1. COMPANY OVERVIEW
26.2.11.2. REVENUE ANALYSIS
26.2.11.3. GEOGRAPHIC PRESENCE
26.2.11.4. PRODUCT PORTFOLIO
26.2.11.5. RECENT DEVELOPMENTS
26.2.12 BIOBASE BIOTECH (JINAN) CO., LTD
26.2.12.1. COMPANY OVERVIEW
26.2.12.2. REVENUE ANALYSIS
26.2.12.3. GEOGRAPHIC PRESENCE
26.2.12.4. PRODUCT PORTFOLIO
26.2.12.5. RECENT DEVELOPMENTS
26.2.13 BAXTER
26.2.13.1. COMPANY OVERVIEW
26.2.13.2. REVENUE ANALYSIS
26.2.13.3. GEOGRAPHIC PRESENCE
26.2.13.4. PRODUCT PORTFOLIO
26.2.13.5. RECENT DEVELOPMENTS
26.2.14 KANEKA CORPORATION
26.2.14.1. COMPANY OVERVIEW
26.2.14.2. REVENUE ANALYSIS
26.2.14.3. GEOGRAPHIC PRESENCE
26.2.14.4. PRODUCT PORTFOLIO
26.2.14.5. RECENT DEVELOPMENTS
26.2.15 SHANGHAI DAHUA MEDICAL APPARATUS CO., LTD
26.2.15.1. COMPANY OVERVIEW
26.2.15.2. REVENUE ANALYSIS
26.2.15.3. GEOGRAPHIC PRESENCE
26.2.15.4. PRODUCT PORTFOLIO
26.2.15.5. RECENT DEVELOPMENTS
26.2.16 ZHENGYUAN TECHNOLOGY CO., LTD.
26.2.16.1. COMPANY OVERVIEW
26.2.16.2. REVENUE ANALYSIS
26.2.16.3. GEOGRAPHIC PRESENCE
26.2.16.4. PRODUCT PORTFOLIO
26.2.16.5. RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
27 RELATED REPORTS
28 CONCLUSION
29 QUESTIONNAIRE
30 ABOUT DATA BRIDGE MARKET RESEARCH
